Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Neurocognitive Integrity After Proton Therapy for Brain Tumor (PROTON MIND)

22. September 2026 aktualisiert von: European Institute of Oncology

Prospective Evaluation of Neurocognitive Integrity After Proton Therapy for Brain Tumor

Radiation therapy remains a cornerstone in the management of both benign and malignant intracranial tumors, either as monotherapy or combined with surgery and/or chemotherapy. Despite its therapeutic benefits, it is frequently associated with potential long-term adverse effects, with neurotoxicity posing a major challenge, especially in young patients affected by benign primary tumors.

Studienübersicht

Status

Noch keine Rekrutierung

Detaillierte Beschreibung

In the brain, late radiotoxicities typically manifest as cognitive dysfunction, leukoencephalopathy, brain atrophy, brain tissue necrosis, cerebrovascular complications, endocrinopathies, and/or secondary malignant neoplasms.

Radiation-induced hippocampal injury, in particular, significantly contributes to cognitive impairment, while broader central nervous system effects arise through multiple mechanisms, including vascular injury, neuronal depletion, chronic inflammation, demyelination, and tissue necrosis.

The severity of cognitive dysfunction depends on multiple factors, including the location and the volume of the tumor, the total radiation dose administered, the fractionation regimen, and the individual susceptibility of the patient, as well as comorbidities (e.g., diabetes, etc.) and concomitant drugs.

The distinct physical characteristics of proton therapy, such as a reduced entrance dose, an eliminated exit dose, and a Bragg peak, provide clear dosimetric advantages over conventional photon treatments. Pencil-beam scanning further improves on earlier passive scattering approaches by delivering modulated proton beamlets for superior target conformality and reduced neutron scatter, thereby limiting low- and intermediate- dose exposure to cranial organs at risk (OARs) while preserving adequate dose coverage within the target volume.

From a radiobiological standpoint, these properties suggest that proton therapy may present a more favorable risk-benefit balance compared to photon-based modalities, particularly for long-term clinical outcomes. It achieves a drastic reduction in the integral dose, offering substantial benefit in decreasing radiation-induced second malignancies, making it mandatory for children when available.

Proton therapy is well established for treating pediatric tumors, CNS tumors such as low-grade gliomas (LGG) and meningiomas, especially if near the optic pathway or brainstem, and all the benign tumors in young patients. In these cases, the primary goal extends beyond curing the disease to preserving neurological and cognitive functions.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

60

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Italy
      • Milan, Italy, Italien, 20141
        • European Institute of Oncology, Milan

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients affected by primary central nervous system tumors and eligible for protontherapy as adjuvant or radical treatment

Beschreibung

Inclusion Criteria:

  • Primary tumors of Brain Tumor (CNS), benign and malignant
  • Age ≥ 18 years
  • Patients able to speak and read the local language(s) fluently
  • Acceptance and signature of informed consent
  • Radiological diagnosis, biopsy, or previous surgery
  • Concomitant medical therapy is allowed

Exclusion Criteria:

  • Previous brain radiotherapy (any form)
  • High-grade gliomas
  • Patients with concomitant neurological or psychiatric disorders.
  • Pregnancy

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
The presence of cognitive impairment
Zeitfenster: From the end of Protontherapy through study completion, an average of 1 year.

The primary endpoint will be the presence of cognitive impairment during the first 5 years after enrollment, as measured by a comprehensive neuropsychological assessment.

From the end of Protontherapy through study completion, an average of 1 year.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Perceived cognitive impairment
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Functional Assessment of Cancer Therapy-cognition (FACT-cog) 37 items will be completed (score 1-4)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Depressive symptoms
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

At Beck Depression Inventory-II (BDI-II) 21 items will be completed (score 0-3)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Anxiety
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For State-Trait Anxiety Inventory (STAI) 40 items will be completed (score 1-4)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Quality of Life data (QoL) - EORTC QLQ C30 questionnaires.
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For EORTC QLQ C30, 30 items will be completed (score 1-4).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Sleep quality
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Pittsburgh Sleep Quality Index (PSQI) 24 items will be completed (score 0-3)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Cognitive Reserve
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Cognitive Reserve Index questionnaire (CRIq) 20 items will be completed (core 0-1)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Global functioning
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Montreal Cognitive Assessment (MoCA) 30 items will be completed (score 1-5).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Learning and Verbal Memory
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Rey Auditory Verbal Learning Test (RAVLT) 15 items will be completed (score 0-4).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Working memory
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Corsi Span backward/forward 18 items will be completed (score 0-4).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Visual memory
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Rey-Osterrieth complex figure -recall 18 items will be completed (score 0-2).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Visuospatial abilities
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Rey-Osterrieth complex figure -copy 18 items will be completed (score 0-2).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Executive function
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Frontal Assessment Battery (FAB) 30 items will be completed (score 0-3).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Attention
Zeitfenster: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Symbol digit modalities test (SDMT) 110 items will be completed (score 0-1)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. September 2026

Primärer Abschluss (Geschätzt)

1. Juli 2031

Studienabschluss (Geschätzt)

1. Juli 2036

Studienanmeldedaten

Zuerst eingereicht

14. September 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. September 2026

Zuerst gepostet (Tatsächlich)

23. September 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

23. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. September 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • UID 5445
  • L2-684 (Andere Kennung: Comitato Etico Lombardia 2)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren